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of treating minor bleeding adverse events related to VTEp was estimated as
USD$2679 and major bleeding was USD$5564. Similar estimations were found for
knee replacement events. CONCLUSIONS: The occurrence of VTE events related to
orthopedic surgery can significantly impact the costs of surgery, particularly given
that in Argentina the cost of hip replacement was estimated as USD $1959 and the
cost of knee replacement as USD $1193. One must therefore consider treatments
given for VTE prevention, as these therapies not only impact survival and quality of
life but can also substantially impact the efficient use of health care resources.
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OBJECTIVES:To evaluate the healthcare cost for themanagement of diabetes along
with other co-morbidities condition.METHODS: A cross-sectional study was con-
ducted in the Community setup of Warangal, India for a period of three months.
Only the educated Diabetic patients with other comorbidities were enrolled in the
study. The data collected were cost of medications, lab tests, consultation fee,
transportation cost. The average total healthcare cost was calculated based on the
previous two months expenses of each patient. RESULTS: A total of 100 patients
were evaluated in the study period. Out of 100 patients, majorities were in the age
group of 41-61 yrs 66 (66%) and also found to be higher in men 63 (63%) than in
women 37 (37%). Most of the patients were diabetes with hypertension, dyslipide-
mia. The average cost of medications per patient Rs. 1540 (72.81%), the average
laboratory cost per patient Rs. 350 (16.55%), the average doctors consultation fee
per patient Rs.175 (8.27%), the average transportation charges per patient Rs.50
(2.36%). The most common drugs prescribed in the study were Metformin, Gliben-
clamide, Gliclazide, Insulin, Ramipril, Amlodipine, Telmisartan, Metoprolol, Hy-
drochlorothiazide, Furosemide, Atorvastatin and Aspirin. The most common lab-
oratory test includes FBS/PPBS/RBS/HbA1C, lipid profiles, urine analysis, Hb,
Electrolytes and Sr.Creatinine. The average total healthcare cost for two months
was found to be Rs.2115 per patient. CONCLUSIONS: In summary, this is the first
Indian healthcare cost study conducted in the community setup. Diabetes imposes
an enormous economic burden on the healthcare system worldwide. This burden
will continue to increase in the next two decades. More prevention efforts and
resources are required to reduce this burden and to provide basic diabetes care in
the low- and middle-income countries.
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OBJECTIVES: The management of arterial hypertension in France starts with an
evaluation of the patient’s cardiovascular risk (function of age, sex, cholesterol
level, systolic blood pressure [SBP]) and if necessary, the prescription of a recom-
mended class among angiotensin converting enzyme (ACE)-inhibitors, angiotensin
receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCB) and thia-
zide diuretics. The objective of this study was to assess, for different patient’s
profiles, the cost-effectiveness of the recommended antihypertensive classes in
France. METHODS: A cohort of newly treated patients entered a Markov model,
using 1-month cycles in the first year, 1-year cycles until 10 years then lifetime
extrapolation of costs and benefits. The cohort was characterized by its cardiovas-
cular risk, evaluated via the France-specific Framingham equation. The risk reduc-
tions per class versus placebowere taken from themost recentmeta-analyses. The
probability to switch from monotherapy to bitherapy and tritherapy was depend-
ing on the achieved SBP (target 140mmHg) and the class-specific persistence. Na-
tional health care databases provided persistence and costs data. Discount rate
was 4% (costs and life-years). RESULTS: In low-risk patients (65-year-old female,
SBP 150mmHg), incremental cost-effectiveness vs. placebo ranged from 101€/life-
year gained (ACE-inhibitors followed by ACE-inhibitors/thiazides) to 7,722€/life-
year gained (beta-blockers followed by beta-blockers/CCB). Savings and extra ben-
efits vs. placebo were obtained in high-risk patients (74-year-old diabetic male,
smokers, SBP 180mmHg): up to 0.57 life-years gained with total costs reduced from
17,630€ to 15,403€ (ACE-inhibitors followed by ACE-inhibitors/CCB, least expensive
sequence) and 15,953€ (beta-blockers followed by beta-blockers/ARBs,most expen-
sive sequence). The classes rankingwas influenced by the persistence and diabetes
incidence. The differenceswere significant vs. placebo but not between the classes,
as per probabilistic sensitivity analysis. CONCLUSIONS: This lifetime model sug-
gests that all recommended anti-hypertensive drugs in France are very cost-effec-
tive versus placebo, and, in higher-risk patients, are even cost-saving with savings
comparable among the classes.
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a chronic disease charac-
terized by progressive elevation of pulmonary artery pressure and vascular resis-
tance, leading to right-sided heart failure and premature death. The objective
of the present research was to assess the clinical and economic aspects of current
oral treatments options for PAH, New York Heart Association (NYHA) functional
classes II and III, from the Brazilian Public Health Systemperspective.METHODS:A
literature review was conducted on the efficacy and safety of ambrisentan, bosen-
tan and sildenafil in patients diagnosed with PAH, in order to support the assump-
tion of clinical equivalence between the treatments and the development of a
cost-minimization analysis. The clinical outcome of interest was improvement in
the distance (in meters) walked in 6 minutes (6MWD). For the economic analysis,
direct medical costs were considered. Treatment, diagnostic, and procedure costs
were obtained from public price/reimbursement databases. Government acquisi-
tion prices were used for all drugs. Costs associated with adverse drug reactions
and treatment withdrawals were also considered. A one-year time-horizon was
used and all costs were presented in 2011 Brazilian currency (1BRL0.60USD).
RESULTS: There were no studies directly comparing any of the targeted agents.
Thus, an indirect comparison of placebo controlled trials of selected PAH therapies
was conducted. Standardized mean differences (SMD) between agents (over pla-
cebo) was calculated and the magnitude of effects between the comparators sug-
gested similar clinical efficacy over 12–16 weeks of treatment. Confidence intervals
of treatment effects overlapped substantially and supported the clinical assump-
tion. The total annual/monthly costs for the interventions were R$13,169.76/
R$1,097.48 for ambrisentan, R$13,226.86/R$1,102.24 for sildenafil, and R$30,227.70/
R$2,518.98 for bosentan. CONCLUSIONS: Ambrisentan was identified as the
alternativewith the lowest cost and similar clinical outcomes comparedwith other
selected therapies for treating patients diagnosed with PAH, NYHA functional
classes II and III, under the Brazilian public perspective.
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OBJECTIVES: To compare costs and effectiveness of dabigatran etexilate (DAB)
versus acetylsalicilic acid (ASA) in patients with Non-Valvular Atrial Fibrillation
(NVAF) from a private and public health care system perspective in Brazil.
METHODS: AMarkov model was built to compare DAB versus ASA to derive incre-
mental cost effectiveness ratio (ICER) of DAB based on a mixed treatment compar-
ison and a modified Delphi panel with Brazilian experts (local clinical practice
pattern on themanagement ofNVAFpatients). Themodel estimated the number of
ischaemic and haemorrhagic strokes, systemic embolisms, intracranial hemor-
rhages, transient ischaemic attacks, extracranial hemorrhages, minor bleeds and
acute myocardial infarctions associated with the respective treatments. To each
clinical event costs, disabilities and/or reduction in quality of life, and risk of death
were assigned. Only directmedical costs were considered and a discount rate of 5%
was assumed, according to Brazilian HTA guidelines. A probabilistic sensitivity
analysis was designed to assess uncertainty. RESULTS:Under both, the private and
public perspective, DAB was associated with additional 0.31 life years gained (LY),
additional 0.60 QALYs and demonstrated a lower incidence of intracranial events
versus ASP, resulting in a lower event costs (-R$ 1,057.84 and - R$ 3,006.07) and
follow up costs. The ICER for DAB versus ASAwas R$ 38,511.06/LY and R$ 31,379.80/
QALY from the public perspective and DAB was dominant from the private per-
spective. Sensitivity analyses confirmed the cost-effectiveness of DAB.
CONCLUSIONS: Findings suggest that DAB can be cost-effective for stroke preven-
tion when used instead of ASA in NVAF patients in Brazil, given that DAB was
dominant in the private sector and ICERS were below the threshold of other tech-
nologies reimbursed in the public health care sector.
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OBJECTIVES: Although medication advice is a key component in cardiac rehabili-
tation (CR) program, little is known about its effectiveness on patient medication
use behaviors. This project aimed to assess the cost-effectiveness of CR programon
patient adherence to cardiac medication and the number of hospitalization
avoided. METHODS: Using MarketScan® Medicaid database, patients with acute
myocardial infarction (AMI) were targeted. By using propensity scores, 471 patients
receiving CR programs during 2003- 2007were 1:1matchedwith 471 controls (with-
out CR) on patient demographics, comorbidities and healthcare costs before the CR
started. The economic perspective was that of third-payer sector so only direct
medical costs were included (costs attributed to CR program and the use of cardiac
specific medical services and medications). Main outcomes were patient adher-
ence to cardiacmedicationmeasured byMedication Possession Ratio and the num-
ber of cardiac related hospitalization. The cardiac medications studied were 1
selective-blockers, angiotensin converting enzyme inhibitors and angiotensin re-
ceptor blockers. The outcomes were estimated every 4 months during 1-year fol-
low-up. Cost-effectiveness of CR programwas determined by the incremental cost-
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